Cti Biopharma Corp financial data

Industry
Pharmaceutical Preparations
Location
3101 Western Avenue, Suite 800, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
CELL THERAPEUTICS INC (to 5/29/2014)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 187 % +31.7%
Quick Ratio 1.61 %
Debt-to-equity -1.1K % -1734%
Return On Equity 426 %
Return On Assets -55.8 % +54.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 132M shares +32%
Common Stock, Shares, Outstanding 132M shares +31.1%
Entity Public Float 626M USD +197%
Common Stock, Value, Issued 132K USD +30.7%
Weighted Average Number of Shares Outstanding, Basic 132M shares +31.8%
Weighted Average Number of Shares Outstanding, Diluted 132M shares +31.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 75.8M USD +3201%
Cost of Revenue 4.46M USD +1504%
Costs and Expenses 130M USD +12.1%
Operating Income (Loss) -53.9M USD +52.4%
Nonoperating Income (Expense) -15.3M USD -244%
Net Income (Loss) Attributable to Parent -69.2M USD +41.2%
Earnings Per Share, Basic -0.54 USD/shares +56.1%
Earnings Per Share, Diluted -0.54 USD/shares +56.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24.2M USD -75%
Cash, Cash Equivalents, and Short-term Investments 59M USD -39.1%
Accounts Receivable, after Allowance for Credit Loss, Current 23M USD +846%
Inventory, Net 777K USD +662%
Assets, Current 86.5M USD -16.3%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 1.89M USD -32.1%
Intangible Assets, Net (Excluding Goodwill) 22.7M USD -8.5%
Other Assets, Noncurrent 3.11M USD -5.44%
Assets 112M USD -14.6%
Accounts Payable, Current 2.03M USD -16.5%
Employee-related Liabilities, Current 7.21M USD +50.7%
Accrued Liabilities, Current 16.3M USD -65.3%
Liabilities, Current 68.2M USD -31%
Operating Lease, Liability, Noncurrent 1.23M USD -38.8%
Other Liabilities, Noncurrent 1.02M USD -44.2%
Liabilities 138M USD -13.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -35K USD
Retained Earnings (Accumulated Deficit) -2.53B USD -2.81%
Stockholders' Equity Attributable to Parent -16.8M USD -143%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -25.3M USD +9.21%
Liabilities and Equity 112M USD -14.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.1M USD -3.74%
Net Cash Provided by (Used in) Financing Activities 9.63M USD -84.3%
Net Cash Provided by (Used in) Investing Activities 15.3M USD
Common Stock, Shares Authorized 267M shares 0%
Common Stock, Shares, Issued 132M shares +31.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.21M USD -120%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.2M USD -75%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.86M USD +48.5%
Deferred Tax Assets, Valuation Allowance 136M USD +47.2%
Deferred Tax Assets, Gross 137M USD +46.7%
Operating Lease, Liability 2.02M USD -36.6%
Lessee, Operating Lease, Liability, to be Paid 2.31M USD -38.5%
Property, Plant and Equipment, Gross 2.35M USD -59%
Operating Lease, Liability, Current 811K USD -1.34%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1M USD +2.66%
Lessee, Operating Lease, Liability, to be Paid, Year One 975K USD -32.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 299K USD -49.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 337K USD -66.4%
Deferred Tax Assets, Operating Loss Carryforwards 56M USD +39.7%
Preferred Stock, Shares Authorized 33.3K shares 0%
Unrecognized Tax Benefits 2.82M USD +133%
Additional Paid in Capital 2.51B USD +2.95%
Deferred Tax Assets, Net of Valuation Allowance 961K USD -4.95%
Interest Expense 15.3M USD +256%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%